Cargando…

Long-Term Follow-Up of Fractional CO(2) Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors

(1) Background: The objective of this study was to determine the long-term efficacy of fractional CO(2) laser therapy in breast cancer survivors. (2) Methods: This was a single-arm study of breast cancer survivors. Participants received three treatments of fractional CO(2) laser therapy and returned...

Descripción completa

Detalles Bibliográficos
Autores principales: Quick, Allison M., Hundley, Andrew, Evans, Cynthia, Stephens, Julie A., Ramaswamy, Bhuvaneswari, Reinbolt, Raquel E., Noonan, Anne M., Van Deusen, Jeffrey Bryan, Wesolowski, Robert, Stover, Daniel G., Williams, Nicole Olivia, Sardesai, Sagar D., Faubion, Stephanie S., Loprinzi, Charles L., Lustberg, Maryam B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836519/
https://www.ncbi.nlm.nih.gov/pubmed/35160226
http://dx.doi.org/10.3390/jcm11030774
_version_ 1784649699492364288
author Quick, Allison M.
Hundley, Andrew
Evans, Cynthia
Stephens, Julie A.
Ramaswamy, Bhuvaneswari
Reinbolt, Raquel E.
Noonan, Anne M.
Van Deusen, Jeffrey Bryan
Wesolowski, Robert
Stover, Daniel G.
Williams, Nicole Olivia
Sardesai, Sagar D.
Faubion, Stephanie S.
Loprinzi, Charles L.
Lustberg, Maryam B.
author_facet Quick, Allison M.
Hundley, Andrew
Evans, Cynthia
Stephens, Julie A.
Ramaswamy, Bhuvaneswari
Reinbolt, Raquel E.
Noonan, Anne M.
Van Deusen, Jeffrey Bryan
Wesolowski, Robert
Stover, Daniel G.
Williams, Nicole Olivia
Sardesai, Sagar D.
Faubion, Stephanie S.
Loprinzi, Charles L.
Lustberg, Maryam B.
author_sort Quick, Allison M.
collection PubMed
description (1) Background: The objective of this study was to determine the long-term efficacy of fractional CO(2) laser therapy in breast cancer survivors. (2) Methods: This was a single-arm study of breast cancer survivors. Participants received three treatments of fractional CO(2) laser therapy and returned for a 4 week follow-up. Participants were contacted for follow-up at annual intervals. The Vaginal Assessment Scale (VAS), the Female Sexual Function Index (FSFI), the Female Sexual Distress Scare Revised (FSDS-R), the Urinary Distress Inventory (UDI), and adverse events were collected and reported for the two-year follow-up. The changes in scores were compared between the four-week and two-year and the one-year and two-year follow-ups using paired t-tests. (3) Results: In total, 67 BC survivors were enrolled, 59 completed treatments and the four week follow-up, 39 participated in the one-year follow-up, and 33 participated in the two-year follow-up. After initial improvement in the VAS from baseline to the four week follow-up, there was no statistically significant difference in the VAS score (mean Δ 0.23; 95% CI [−0.05, 0.51], p = 0.150) between the four week follow-up and the two-year follow-up. At the two-year follow-up, the FSFI and FSDS-R scores remained improved from baseline and there was no statistically significant change in the FSFI score (mean Δ −0.83; 95% CI [−3.07, 2.38] p = 0.794) or the FSDS-R score (mean Δ −2.85; 95% CI [−1.88, 7.59] p = 0.227) from the one to two-year follow-up. The UDI scores approached baseline at the two-year follow-up; however, the change between the one- and two-year follow-ups was not statistically significant (mean Δ 4.76; 95% CI [−1.89, 11.41], p = 0.15). (4) Conclusions: Breast cancer survivors treated with fractional CO(2) laser therapy have sustained improvement in sexual function two years after treatment completion, suggesting potential long-term benefit.
format Online
Article
Text
id pubmed-8836519
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88365192022-02-12 Long-Term Follow-Up of Fractional CO(2) Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors Quick, Allison M. Hundley, Andrew Evans, Cynthia Stephens, Julie A. Ramaswamy, Bhuvaneswari Reinbolt, Raquel E. Noonan, Anne M. Van Deusen, Jeffrey Bryan Wesolowski, Robert Stover, Daniel G. Williams, Nicole Olivia Sardesai, Sagar D. Faubion, Stephanie S. Loprinzi, Charles L. Lustberg, Maryam B. J Clin Med Article (1) Background: The objective of this study was to determine the long-term efficacy of fractional CO(2) laser therapy in breast cancer survivors. (2) Methods: This was a single-arm study of breast cancer survivors. Participants received three treatments of fractional CO(2) laser therapy and returned for a 4 week follow-up. Participants were contacted for follow-up at annual intervals. The Vaginal Assessment Scale (VAS), the Female Sexual Function Index (FSFI), the Female Sexual Distress Scare Revised (FSDS-R), the Urinary Distress Inventory (UDI), and adverse events were collected and reported for the two-year follow-up. The changes in scores were compared between the four-week and two-year and the one-year and two-year follow-ups using paired t-tests. (3) Results: In total, 67 BC survivors were enrolled, 59 completed treatments and the four week follow-up, 39 participated in the one-year follow-up, and 33 participated in the two-year follow-up. After initial improvement in the VAS from baseline to the four week follow-up, there was no statistically significant difference in the VAS score (mean Δ 0.23; 95% CI [−0.05, 0.51], p = 0.150) between the four week follow-up and the two-year follow-up. At the two-year follow-up, the FSFI and FSDS-R scores remained improved from baseline and there was no statistically significant change in the FSFI score (mean Δ −0.83; 95% CI [−3.07, 2.38] p = 0.794) or the FSDS-R score (mean Δ −2.85; 95% CI [−1.88, 7.59] p = 0.227) from the one to two-year follow-up. The UDI scores approached baseline at the two-year follow-up; however, the change between the one- and two-year follow-ups was not statistically significant (mean Δ 4.76; 95% CI [−1.89, 11.41], p = 0.15). (4) Conclusions: Breast cancer survivors treated with fractional CO(2) laser therapy have sustained improvement in sexual function two years after treatment completion, suggesting potential long-term benefit. MDPI 2022-01-31 /pmc/articles/PMC8836519/ /pubmed/35160226 http://dx.doi.org/10.3390/jcm11030774 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Quick, Allison M.
Hundley, Andrew
Evans, Cynthia
Stephens, Julie A.
Ramaswamy, Bhuvaneswari
Reinbolt, Raquel E.
Noonan, Anne M.
Van Deusen, Jeffrey Bryan
Wesolowski, Robert
Stover, Daniel G.
Williams, Nicole Olivia
Sardesai, Sagar D.
Faubion, Stephanie S.
Loprinzi, Charles L.
Lustberg, Maryam B.
Long-Term Follow-Up of Fractional CO(2) Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors
title Long-Term Follow-Up of Fractional CO(2) Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors
title_full Long-Term Follow-Up of Fractional CO(2) Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors
title_fullStr Long-Term Follow-Up of Fractional CO(2) Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors
title_full_unstemmed Long-Term Follow-Up of Fractional CO(2) Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors
title_short Long-Term Follow-Up of Fractional CO(2) Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors
title_sort long-term follow-up of fractional co(2) laser therapy for genitourinary syndrome of menopause in breast cancer survivors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836519/
https://www.ncbi.nlm.nih.gov/pubmed/35160226
http://dx.doi.org/10.3390/jcm11030774
work_keys_str_mv AT quickallisonm longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT hundleyandrew longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT evanscynthia longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT stephensjuliea longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT ramaswamybhuvaneswari longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT reinboltraquele longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT noonanannem longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT vandeusenjeffreybryan longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT wesolowskirobert longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT stoverdanielg longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT williamsnicoleolivia longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT sardesaisagard longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT faubionstephanies longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT loprinzicharlesl longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors
AT lustbergmaryamb longtermfollowupoffractionalco2lasertherapyforgenitourinarysyndromeofmenopauseinbreastcancersurvivors